The optimal manufacturing site for a drug can change throughout its life cycle. Early in development, biopharma companies often keep production in the US to ensure a localized supply chain and quick delivery. As a product nears the end of its life cycle, the focus shifts to cost-effective, large-scale production without compromising quality.
Selecting manufacturing sites based on a product's life cycle stage benefits patients by ensuring rapid access to new drugs and reducing costs for mature products. The challenge lies in finding sites that meet both specific life cycle needs and universal quality requirements.
Piramal Pharma Solutions (PPS) exemplifies a Contract Development and Manufacturing Organization (CDMO) that supports biopharma companies throughout the product life cycle. With sites in the US, the UK and India maintaining consistent quality systems and capabilities, PPS can efficiently handle both early and late life cycle products. For details, read our whitepaper.
